单克隆抗体行业研究
发布时间：2018-09-17 14:15
【摘要】：本文从三个比较重要的影响因素入手,阐述未来生物制药行业的潜在增长力。再从细分的单克隆抗体子行业入手,叙说该行业目前的国内外状况。 国内的单克隆抗体药物的研究起步较晚,与国外各生物制药公司巨头相比无论在资金还是技术上,都有很大差距。我们纵观国外单抗药物市场,短短10年间,在全球前十大药物销售额排名中,单抗药物产品就占据了一半以上的位置。 而反观国内,由于发展起步比较晚,目前单抗药物市场销售总量不大。但由于单抗药物具有的在肿瘤,自身免疫性疾病等疑难杂症中的巨大疗效和国内患者的刚性需求,近几年增长迅速。 国内单抗企业面对无论是技术还是资金都远远落后的残酷现实,最后通过选择了"Me-too"药物策略来打破这种窘迫的境地。本文通过分析"Me-too"药物策略的可行性,得出中国国内单抗企业具有和国外原研产品一争高低的能力。其中一些一线单抗药物公司更是值得我们关注投资。
[Abstract]:This paper discusses the potential growth of biopharmaceutical industry in the future from three important influencing factors. Then from the subdivision of monoclonal antibody sub-industry, describes the current situation of the industry at home and abroad. The research of monoclonal antibody drugs in China started late, and there is a big gap between the foreign biopharmaceutical companies in terms of funding and technology. In a short period of 10 years, in the world's top ten drug sales rankings, McAbs account for more than half of the world's top ten drug sales. In contrast, domestic, due to the development started relatively late, the current anti-drug market sales volume is not large. However, because of the huge curative effect of monoclonal antibody in cancer, autoimmune diseases and the rigid demand of patients in China, it has been increasing rapidly in recent years. Faced with the cruel reality that both the technology and the capital are far behind, the domestic McAb enterprises finally break this dilemma by choosing the "Me-too" drug strategy. Based on the analysis of the feasibility of "Me-too" drug strategy, it is concluded that the domestic McAb enterprises in China have the ability to compete with the original developed products of foreign countries. Some of the first-line anti-drug companies are worth our attention to invest.
【学位授予单位】：西南财经大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.44;F416.72
本文编号：2246187
[Abstract]:This paper discusses the potential growth of biopharmaceutical industry in the future from three important influencing factors. Then from the subdivision of monoclonal antibody sub-industry, describes the current situation of the industry at home and abroad. The research of monoclonal antibody drugs in China started late, and there is a big gap between the foreign biopharmaceutical companies in terms of funding and technology. In a short period of 10 years, in the world's top ten drug sales rankings, McAbs account for more than half of the world's top ten drug sales. In contrast, domestic, due to the development started relatively late, the current anti-drug market sales volume is not large. However, because of the huge curative effect of monoclonal antibody in cancer, autoimmune diseases and the rigid demand of patients in China, it has been increasing rapidly in recent years. Faced with the cruel reality that both the technology and the capital are far behind, the domestic McAb enterprises finally break this dilemma by choosing the "Me-too" drug strategy. Based on the analysis of the feasibility of "Me-too" drug strategy, it is concluded that the domestic McAb enterprises in China have the ability to compete with the original developed products of foreign countries. Some of the first-line anti-drug companies are worth our attention to invest.
【学位授予单位】：西南财经大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.44;F416.72
【参考文献】
相关期刊论文 前9条
1 艾静;生物医药产业前景灿烂[J];中国创业投资与高科技;2004年03期
2 国家发展和改革委员会中国生物产业发展战略研究课题组;世界生物产业发展趋势及战略[J];中国创业投资与高科技;2004年11期
3 张醒洲,王春艳;生物制药企业成功要素[J];大连理工大学学报(社会科学版);2002年04期
4 张蕊,田澎;生物制药产业现状分析及我国企业的发展战略[J];工业工程与管理;2005年05期
5 张本波;我国人口老龄化的经济社会后果分析及政策选择[J];宏观经济研究;2002年03期
6 胡显文,陈惠鹏,汤仲明,马清钧;美国、欧盟和中国生物技术药物的比较[J];中国生物工程杂志;2005年02期
7 严朝贵;中国医药市场发展的趋势[J];上海医药;2001年03期
8 陈镜波;繁星闪烁的“医药银河”——日本医药产业发展概况[J];首都医药;2001年05期
9 黄昕,张多来;WTO挑战中国制药工业[J];中国卫生事业管理;2000年05期
，本文编号：2246187
本文链接：https://www.wllwen.com/jingjilunwen/gongyejingjilunwen/2246187.html
